Simon Croft
Simon Croft
Verified email at
Cited by
Cited by
Drug resistance in leishmaniasis
SL Croft, S Sundar, AH Fairlamb
Clinical microbiology reviews 19 (1), 111-126, 2006
Antimalarial drug discovery: efficacy models for compound screening
DA Fidock, PJ Rosenthal, SL Croft, R Brun, S Nwaka
Nature reviews Drug discovery 3 (6), 509-520, 2004
Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs
SL Croft, GH Coombs
Trends in parasitology 19 (11), 502-508, 2003
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda
PJ Guerin, P Olliaro, S Sundar, M Boelaert, SL Croft, P Desjeux, ...
The Lancet infectious diseases 2 (8), 494-501, 2002
Kinetoplastids: related protozoan pathogens, different diseases
K Stuart, R Brun, S Croft, A Fairlamb, RE Gürtler, J McKerrow, S Reed, ...
The Journal of clinical investigation 118 (4), 1301-1310, 2008
Current scenario of drug development for leishmaniasis.
SL Croft, K Seifert, V Yardley
The Indian journal of medical research 123 (3), 399-410, 2006
Chemotherapy of trypanosomiases and leishmaniasis
SL Croft, MP Barrett, JA Urbina
Trends in parasitology 21 (11), 508-512, 2005
Chemotherapy of leishmaniasis
SL Croft, V Yardley
Current pharmaceutical design 8 (4), 319-342, 2002
Natural products as antiparasitic drugs
O Kayser, AF Kiderlen, SL Croft
Parasitology research 90 (2), S55-S62, 2003
Leishmaniasis chemotherapy—challenges and opportunities
SL Croft, P Olliaro
Clinical microbiology and infection 17 (10), 1478-1483, 2011
Leishmaniasis: new approaches to disease control
CR Davies, P Kaye, SL Croft, S Sundar
Bmj 326 (7385), 377-382, 2003
Bisphosphonates Inhibit the Growth of Trypanosoma b rucei, Trypanosoma c ruzi, Leishmania d onovani, Toxoplasma g ondii, and Plasmodium f alciparum: A Potential Route to …
MB Martin, JS Grimley, JC Lewis, HT Heath, BN Bailey, H Kendrick, ...
Journal of medicinal chemistry 44 (6), 909-916, 2001
Management of trypanosomiasis and leishmaniasis
MP Barrett, SL Croft
British medical bulletin 104 (1), 175-196, 2012
Structure–activity relationships of antileishmanial and antimalarial chalcones
M Liu, P Wilairat, SL Croft, ALC Tan, ML Go
Bioorganic & medicinal chemistry 11 (13), 2729-2738, 2003
Chemotherapy in the treatment and control of leishmaniasis
J Alvar, S Croft, P Olliaro
Advances in parasitology 61, 223-274, 2006
2-and 3-substituted 1, 4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from trypanosoma c ruzi: Synthesis and …
L Salmon-Chemin, E Buisine, V Yardley, S Kohler, MA Debreu, V Landry, ...
Journal of medicinal chemistry 44 (4), 548-565, 2001
Artemisone—a highly active antimalarial drug of the artemisinin class
RK Haynes, B Fugmann, J Stetter, K Rieckmann, HD Heilmann, HW Chan, ...
Angewandte Chemie International Edition 45 (13), 2082-2088, 2006
The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani
SL Croft, RA Neal, W Pendergast, JH Chan
Biochemical pharmacology 36 (16), 2633-2636, 1987
Formulation of amphotericin B as nanosuspension for oral administration
O Kayser, C Olbrich, V Yardley, AF Kiderlen, SL Croft
International journal of pharmaceutics 254 (1), 73-75, 2003
Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B
P Escobar, S Matu, C Marques, SL Croft
Acta tropica 81 (2), 151-157, 2002
The system can't perform the operation now. Try again later.
Articles 1–20